JPS6255079A - 修飾ウリカ−ゼ - Google Patents
修飾ウリカ−ゼInfo
- Publication number
- JPS6255079A JPS6255079A JP61093855A JP9385586A JPS6255079A JP S6255079 A JPS6255079 A JP S6255079A JP 61093855 A JP61093855 A JP 61093855A JP 9385586 A JP9385586 A JP 9385586A JP S6255079 A JPS6255079 A JP S6255079A
- Authority
- JP
- Japan
- Prior art keywords
- uricase
- modified
- molecule
- molecular weight
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010092464 Urate Oxidase Proteins 0.000 title claims abstract description 35
- 125000003827 glycol group Chemical group 0.000 claims abstract 2
- 125000003277 amino group Chemical group 0.000 claims description 9
- 229920003169 water-soluble polymer Polymers 0.000 abstract description 4
- 230000002255 enzymatic effect Effects 0.000 abstract description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 150000003918 triazines Chemical class 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 7
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940116269 uric acid Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- OMRXVBREYFZQHU-UHFFFAOYSA-N 2,4-dichloro-1,3,5-triazine Chemical compound ClC1=NC=NC(Cl)=N1 OMRXVBREYFZQHU-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61093855A JPS6255079A (ja) | 1986-04-23 | 1986-04-23 | 修飾ウリカ−ゼ |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61093855A JPS6255079A (ja) | 1986-04-23 | 1986-04-23 | 修飾ウリカ−ゼ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4120379A Division JPS55135590A (en) | 1979-04-05 | 1979-04-05 | Modified asparaginase and uricase and their preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6255079A true JPS6255079A (ja) | 1987-03-10 |
| JPH0126677B2 JPH0126677B2 (enrdf_load_stackoverflow) | 1989-05-24 |
Family
ID=14094032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61093855A Granted JPS6255079A (ja) | 1986-04-23 | 1986-04-23 | 修飾ウリカ−ゼ |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6255079A (enrdf_load_stackoverflow) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002522399A (ja) * | 1998-08-06 | 2002-07-23 | マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド | Ｐｅｇ−尿酸酸化酵素結合体およびその使用 |
| JP2003521937A (ja) * | 2000-02-10 | 2003-07-22 | マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド | 非免疫原性ポリマー結合体の調製のための凝集体非含有尿酸オキシダーゼ |
| WO2006110819A2 (en) | 2005-04-11 | 2006-10-19 | Savient Pharmaceuticals, Inc. | Variant forms of urate oxidase and use thereof |
| US7229810B2 (en) | 2001-06-28 | 2007-06-12 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of proteinases |
| EP2158923A1 (en) | 1998-08-06 | 2010-03-03 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
| US7811800B2 (en) | 2005-04-11 | 2010-10-12 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
| US8066985B2 (en) | 1999-02-24 | 2011-11-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| US9534013B2 (en) | 2006-04-12 | 2017-01-03 | Horizon Pharma Rheumatology Llc | Purification of proteins with cationic surfactant |
| US10139399B2 (en) | 2009-06-25 | 2018-11-27 | Horizon Pharma Rheumatology Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
-
1986
- 1986-04-23 JP JP61093855A patent/JPS6255079A/ja active Granted
Cited By (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2316475A1 (en) | 1998-08-06 | 2011-05-04 | Mountain View Pharmaceuticals, Inc. | Isolated tetrameric uricase |
| US7927589B2 (en) | 1998-08-06 | 2011-04-19 | Mountain View Pharmaceuticals, Inc. | PEG-urate oxidase conjugates and use thereof |
| US9885024B2 (en) | 1998-08-06 | 2018-02-06 | Duke University | PEG-urate oxidase conjugates and use thereof |
| US8067553B2 (en) | 1998-08-06 | 2011-11-29 | Mountain View Pharmaceuticals, Inc. | PEG-urate oxidase conjugates and use thereof |
| EP2158923A1 (en) | 1998-08-06 | 2010-03-03 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
| US7723089B2 (en) | 1998-08-06 | 2010-05-25 | Mountain View Pharmaceuticals, Inc. | PEG-urate oxidase conjugates and use thereof |
| US8618267B2 (en) | 1998-08-06 | 2013-12-31 | Mountain View Pharmaceuticals, Inc. | PEG-urate oxidase conjugates and use thereof |
| US7927852B2 (en) | 1998-08-06 | 2011-04-19 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| US8921064B2 (en) | 1998-08-06 | 2014-12-30 | Mountain View Pharmaceuticals, Inc. | Method for purifying urate oxidase tetramers and octamers |
| JP2002522399A (ja) * | 1998-08-06 | 2002-07-23 | マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド | Ｐｅｇ−尿酸酸化酵素結合体およびその使用 |
| US8709443B2 (en) | 1999-02-24 | 2014-04-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US8066985B2 (en) | 1999-02-24 | 2011-11-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US8071087B2 (en) | 1999-02-24 | 2011-12-06 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| JP2003521937A (ja) * | 2000-02-10 | 2003-07-22 | マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド | 非免疫原性ポリマー結合体の調製のための凝集体非含有尿酸オキシダーゼ |
| US7229810B2 (en) | 2001-06-28 | 2007-06-12 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of proteinases |
| US8541205B2 (en) | 2005-04-11 | 2013-09-24 | Savient Pharmaceuticals, Inc. | Variant forms of urate oxidase and use thereof |
| WO2006110819A2 (en) | 2005-04-11 | 2006-10-19 | Savient Pharmaceuticals, Inc. | Variant forms of urate oxidase and use thereof |
| US8188224B2 (en) | 2005-04-11 | 2012-05-29 | Savient Pharmaceuticals, Inc. | Variant forms of urate oxidase and use thereof |
| US8293228B2 (en) | 2005-04-11 | 2012-10-23 | Savient Pharmaceuticals Inc. | Variant form of urate oxidase and use thereof |
| US8465735B2 (en) | 2005-04-11 | 2013-06-18 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
| US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| US8034594B2 (en) | 2005-04-11 | 2011-10-11 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
| US7964381B2 (en) | 2005-04-11 | 2011-06-21 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
| US7811800B2 (en) | 2005-04-11 | 2010-10-12 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
| US9017980B2 (en) | 2005-04-11 | 2015-04-28 | Crealta Pharmaceuticals Llc | Variant forms of urate oxidase and use thereof |
| EP2947145A1 (en) | 2005-04-11 | 2015-11-25 | Crealta Pharmaceuticals LLC | Variant forms of urate oxidase and use thereof |
| US11781119B2 (en) | 2005-04-11 | 2023-10-10 | Horizon Therapeutics Usa, Inc. | Variant forms of urate oxidase and use thereof |
| US9670467B2 (en) | 2005-04-11 | 2017-06-06 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
| US8178334B2 (en) | 2005-04-11 | 2012-05-15 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
| US9926537B2 (en) | 2005-04-11 | 2018-03-27 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
| US9926538B2 (en) | 2005-04-11 | 2018-03-27 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
| EP3321359A1 (en) | 2005-04-11 | 2018-05-16 | Crealta Pharmaceuticals LLC | Variant forms of urate oxidase and use thereof |
| US11345899B2 (en) | 2005-04-11 | 2022-05-31 | Horizon Therapeutics Usa, Inc. | Variant forms of urate oxidase and use thereof |
| US10160958B2 (en) | 2005-04-11 | 2018-12-25 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
| US10731139B2 (en) | 2005-04-11 | 2020-08-04 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
| US9534013B2 (en) | 2006-04-12 | 2017-01-03 | Horizon Pharma Rheumatology Llc | Purification of proteins with cationic surfactant |
| US10139399B2 (en) | 2009-06-25 | 2018-11-27 | Horizon Pharma Rheumatology Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
| US11598767B2 (en) | 2009-06-25 | 2023-03-07 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| US11639927B2 (en) | 2009-06-25 | 2023-05-02 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
| US11982670B2 (en) | 2009-06-25 | 2024-05-14 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| US12188927B2 (en) | 2009-06-25 | 2025-01-07 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0126677B2 (enrdf_load_stackoverflow) | 1989-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI322184B (en) | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates | |
| KR100295520B1 (ko) | 피이지(peg)-인터페론결합체 | |
| US20050014240A1 (en) | Aggregate-free protein compositions and methods of preparing same | |
| JPS6255079A (ja) | 修飾ウリカ−ゼ | |
| JP2002506833A (ja) | 治療薬のｉｎｖｉｖｏデリバリー用担体 | |
| EA018044B1 (ru) | Антитело, специфичное в отношении интерлейкина-6 (ил-6) человека | |
| CN111909906B (zh) | 聚乙二醇修饰的尿酸氧化酶 | |
| JP2002522399A (ja) | Ｐｅｇ−尿酸酸化酵素結合体およびその使用 | |
| CN106554948A (zh) | 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用 | |
| EP3417881A1 (en) | Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof | |
| EP0210761A1 (en) | Modified enzymes, production and use thereof | |
| Toraya et al. | Acceleration of cleavage of the carbon-cobalt bond of sterically hindered alkylcobalamins by binding to apoprotein of diol dehydrase | |
| WO2006133276A2 (en) | Methods for dissolving cystine stones and reducing cystine in urine | |
| TW200540182A (en) | Altered fibronectin-binding protein of staphylococcus aureus | |
| JP7689573B2 (ja) | ポリエチレングリコール修飾尿酸オキシダーゼの製造方法 | |
| JPS6142558B2 (enrdf_load_stackoverflow) | ||
| CN101591649B (zh) | 甲氧基聚乙二醇修饰的精氨酸脱亚氨酶及其制备与应用 | |
| GB2209340A (en) | Imunoproximity catalysts (catalytic antibodies) | |
| JPS62252800A (ja) | 化学修飾タンパク質の製法 | |
| JPH03204818A (ja) | ヒトａｄｆを含有する医薬組成物 | |
| KR20090001069A (ko) | 생체적합성 고분자 변형체-글루코세레브로시다제 접합체,이의 제조방법 및 이를 포함하는 고셔병 치료용 약학조성물 | |
| CN101096664A (zh) | 一种精氨酸脱酰酶共价修饰物、其制造方法及应用 | |
| JPH02231075A (ja) | デキストラン硫酸修飾スーパーオキシドジスムターゼ | |
| WO2025002334A1 (zh) | 尿酸氧化酶及其聚乙二醇化缀合物的稳定剂及其药物用途 | |
| JPH02231076A (ja) | デキストラン修飾スーパーオキシドジスムターゼ |